The University of Chicago Header Logo

Connection

Gladell P. Paner to Prostate

This is a "connection" page, showing publications Gladell P. Paner has written about Prostate.
Connection Strength

1.505
  1. Non-epithelial neoplasms of the prostate. Histopathology. 2012 Jan; 60(1):166-86.
    View in: PubMed
    Score: 0.315
  2. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114.
    View in: PubMed
    Score: 0.161
  3. Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. Abdom Radiol (NY). 2022 02; 47(2):801-813.
    View in: PubMed
    Score: 0.157
  4. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells. 2020 09 17; 9(9).
    View in: PubMed
    Score: 0.144
  5. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720.
    View in: PubMed
    Score: 0.113
  6. Contribution of Caudal Müllerian Duct Mesenchyme to Prostate Development. Stem Cells Dev. 2016 11 15; 25(22):1733-1741.
    View in: PubMed
    Score: 0.110
  7. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.
    View in: PubMed
    Score: 0.101
  8. Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013 Mar 08; 339(6124):1219-24.
    View in: PubMed
    Score: 0.086
  9. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma. J Urol. 2013 Jan; 189(1):53-8.
    View in: PubMed
    Score: 0.084
  10. NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma. Adv Anat Pathol. 2024 May 01; 31(3):202-205.
    View in: PubMed
    Score: 0.046
  11. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.
    View in: PubMed
    Score: 0.045
  12. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160.
    View in: PubMed
    Score: 0.041
  13. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res. 2018 08 01; 24(15):3668-3680.
    View in: PubMed
    Score: 0.031
  14. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
    View in: PubMed
    Score: 0.030
  15. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701.
    View in: PubMed
    Score: 0.021
  16. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res. 2012 Aug 15; 18(16):4291-302.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.